Email this article 
Correction of Stevens-Jonson syndrome - an adverse event of antibiotic therapy
- Authors: Fatenkov OV1, Kuzmina TM1, Rubanenko OA1, Lobankova OI1,2, Arsenjeva EA1,2
-
Affiliations:
- Samara state medical university
- Samara medical sanitary unit No. 6
- Issue: Vol 12, No 6 (2015)
- Pages: 68-71
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2015
- URL: https://rusalljournal.ru/raj/article/view/400
- DOI: https://doi.org/10.36691/RJA400
- ID: 400
Cite item
Open Access
Access granted
Abstract
Stevens-Johnson syndrome refers to the type B of adverse reactions to drugs according to WHO classification and is severe systemic allergic reaction of delayed type. This syndrome is a severe variant of multiform erythema in which both skin and mucous membranes symptoms are observed. In the article literature data on etiology, pathogenesis and treatment of Stevens-Johnson syndrome as well as clinical case of 24 years old woman with this syndrome are represented.
Full Text
About the authors
O V Fatenkov
Samara state medical university
T M Kuzmina
Samara state medical university
O A Rubanenko
Samara state medical university
Email: olesya.rubanenko@gmail.com
O I Lobankova
Samara state medical university; Samara medical sanitary unit No. 6
E A Arsenjeva
Samara state medical university; Samara medical sanitary unit No. 6
References
- Солошенко Э.И. Лекарственная болезнь в проблеме побочного действия лекарственных средств: современное состояние. Дискуссионные вопросы диагностики и лечения. Международный медицинский журнал. 2012, № 3, с. 80-88.
- Эйберман А.С. Лекарственная болезнь у детей. Bulletin of Medical Internet Conferences (ISSN 2224-6150). 2012, v. 2, p. 826-828.
- Mirakian R., Ewan P.W., Durhamw S.R. et al. BSACI guidelines for the management of drug allergy. Clinical and Experimental Allergy. 2009, v. 39, p. 43-61.
- Федеральные и клинические рекомендации по диагностике и лечению лекарственной аллергии. М., 2014. http://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/la.pdf.
- Горячкина Л.А., Астафьева Н.Г., Передкова Е.В. Лекарственная аллергия. В кн.: Клиническая аллергология и иммунология: руководство для практикующих врачей. Под ред. Л.А. Горячкиной и К.П. Кашкина. М.: «Миклош». 2009, с. 363-381.
- Chung W.H., Hung S.I. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J. Dermatol. Sci. 2012, v. 66, p. 190-196.
- Chung W.H., Hung S.I., Yang J.Y. et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens- Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 2008, v. 14, p. 1343-1350.
- Aihara M., Kano J., Fujita H. et al. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. J. Dermatol. 2015, v. 42, p. 768-777.
- Hirahara K., Kano Y., Sato Y et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J. Am. Acad. Dermatol. 2013, v. 69, p. 496-498.
- Lee H.Y., Dunant A., Sekula P. et al. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br. J. Dermatol. 2012, v. 167, p. 555-562.
- Barron S.J., Del Vecchio M.T, Aronoff S.C. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int. J. Dermatol. 2015, v. 54, p. 108-115.
Supplementary files
